

# Press Release

7 January 2011

## ProStrakan Group plc (the "Company") Result of resolutions passed at General Meeting ("General Meeting") of the Company

The Company announces the results of voting on the resolutions (the "**Resolutions**") at its general meeting held on Friday 7 January 2011. The Resolutions relate to the proposed refinancing, assignment and amendment of the Group's Existing Loan Facility described in more detail in the circular (the "**Circular**") to shareholders dated 21 December 2010.

Resolutions 1 and 2 were passed on a show of hands as ordinary resolutions and resolution 3 was passed on a show of hands as a special resolution. Details of the proxy votes received by the Company before the General Meeting in respect of each resolution are set out below.

A copy of the Resolutions will shortly be available for viewing on the investors section of the Company's website at [www.prostrakan.com](http://www.prostrakan.com). A copy of the Resolutions will also be submitted to the National Storage Mechanism and will shortly be available for inspection at [www.hemscott.com/nsm](http://www.hemscott.com/nsm).

It is expected that the Proposals as defined and referred to in the Circular will become unconditional on, and will complete on, 12 January 2011.

### Proxies received in respect of the Resolutions:

<u>Resolution</u>	<u>For</u>	<u>Discretionary</u>	<u>Against</u>	<u>Vote withheld</u>
1. Approval of the Proposals for the purposes of Rule 21.1 of the Takeover Code.	153,744,351 (85.58%)	132,338 (0.07%)	25,788,803 (14.35%)	62,803
2. To authorise the directors to allot shares	153,758,545 (85.59%)	139,821 (0.08%)	25,749,626 (14.33%)	80,303
3. To disapply statutory pre-emption rights.	153,461,896 (85.42%)	139,821 (0.08%)	26,043,275 (14.50%)	83,303

**Ends**

### Enquiries:

<b>ProStrakan</b>	+44 (0) 1896 664000
Peter Allen, Chairman & Acting Chief Executive	
Allan Watson, Chief Financial Officer	
Callum Spreng, Corporate Communications	

<b>Brunswick Group (for ProStrakan)</b>	+44 (0) 20 7404 5959
Justine McIlroy	

**About ProStrakan:**

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centred in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

You can learn more about ProStrakan's business at: [www.prostrakan.com](http://www.prostrakan.com)